Page 17 - Pharmaceutical Firms

Torrent, Zydus collaborate to bring liver disease treatment to India

Saroglitazar Mg received approval in March 2020 for NASH treatment and later expanded its indications to include NAFLD

Novavax plans to slash costs by another $300 mn amid sagging demand

Novavax shares rose 3.1% at 10:26 a.m. in New York after the company's third-quarter loss per share and revenue were better than analysts expected

Glenmark Pharmaceuticals receives USFDA approval for generic Prolixin

Prolixin is a prescription medication used to treat schizophrenia and other mental/mood disorders

Lupin's net profit jumps nearly four-fold on strong US growth, stock up

US sales cross $200 million for the first time in two years, beat analyst expectations

Lupin introduces generic version of Zemuron Injection in United States

The newly introduced Rocuronium Bromide Injection is available in two formulations

Cipla announces transfer of Generics Business Undertaking to subsidiary

The generics business contributed 9.95 per cent of Cipla's turnover and 0.92 per cent of its net worth in the financial year ended March 31, 2023

Alkem Laboratories posts 87.85% increase in PAT, sales in India up by 5%

On a sequential basis, the company exhibited a 16.26 per cent increase in revenue

Should touch Rs 1K crore from OTC this year, says Nandini Piramal

The benefit of having patented products contract manufacturing is that there is always growth, said Piramal

Gland Pharma Q2 result: Net profit fell 20% to Rs 194 cr on higher expenses

Gland Pharma reported a nearly 32% jump in revenue from operations to Rs 1,373 crore, driven by higher sales from the acquisition of the French pharmaceutical group Cenexi in January

Sun Pharmaceutical's vital signs: A strong dose of valuation multiples

The specialty segment and domestic business act as the lifeblood, coursing through the largest pharma company in the country, fuelling both revenue and margins

Lupin receives approval from the US FDA for its Selexipag for injection

In 2022, sales of the Selexipag Franchise in the US stood at $ 1.1 billion. The sales for January 1 to September 30, 2023, stood at $978 million

US sales momentum, margin gains to support pharma major Cipla's stock

Led by the US market which rose by 31 per cent, the company posted a 16 per cent growth in revenues

Pfizer Q2 results: Net profit declines 52% at Rs 149 cr, revenue slips 9.8%

Drug firm Pfizer Ltd on Saturday reported 52.11 per cent decline in net profit at Rs 148.96 crore for the second quarter ended September 2023. The company had logged a net profit of Rs 311.07 crore in July-September period a year ago, according to a regulatory filing by Pfizer. Revenue from operations declined 9.76 per cent to Rs 575.21 crore in the quarter as against Rs 637.47 crore in the year-ago period. Total expense was at Rs 410.76 crore, down 5.66 per cent. Total income was at Rs 611.28 crore in September quarter 2023-24, down 7.62 per cent.

Piramal Pharma clocks 11% revenue growth in quarter ending September

Company's Ebitda grows 44% year-on-year, Chairperson Nandini Piramal anticipates a stronger financial performance in H2

ED raids pharma firm Parabolic Drugs, promoters in money laundering probe

The Enforcement Directorate on Friday carried out raids at multiple premises of Chandigarh-based pharmaceutical company Parabolic Drugs and its promoters as part of a money laundering investigation linked to an alleged bank loan fraud case, official sources said. The searches by the central agency covered a total of 17 premises in Delhi, Mumbai, Chandigarh and Panchkula and Ambala in Haryana, they said. The action is being undertaken under the provisions of the Prevention of Money Laundering Act (PMLA) and the ED case stems from a 2021 CBI FIR against the company and its promoters Vineet Gupta and Pranav Gupta among others, the sources said. The agency, as per the sources, is also looking at some documents from Sonepat-based Ashoka University as two directors of the company, Vineet Gupta and Pranav Gupta, have been associated with the educational institution in the past. The two had stepped down from all the boards and committees of the university in 2022, days after the CBI ...

Fewer generics enter market after linagliptin's patent expiry this August

When Sitagliptin went off patent, nearly 200 brands were vying for a share of the market

2,350 acres set aside for pharma and medical parks in Uttar Pradesh

Chief Minister Yogi Adityanath has envisioned increasing the state's contribution to the pharma industry from 2 per cent to 10-12 per cent

Sun Pharma recalls 144 bottles of anti-depression drug from US market

Sun Pharmaceutical Industries Inc has recalled 144 bottles of a generic anti-depression medicine from the US market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA). The US-based subsdiary of the Mumbai-headquartered drug company initiated the recall for the affected lot of Bupropion Hydrochloride extended-release tablets due to "failed dissolution specifications,", the US health regulator said in its latest Enforcement Report. The affected lot was manufactured at Sun Pharma's Halol-based plant in Gujarat and was distributed in the US by Sun Pharmaceutical Industries Inc, based in Princeton, New Jersy, it said. Bupropion is a medication commonly used to treat depression. The US-based drug maker initiated the voluntary Class III nationwide (US) recall on October 4 this year. As per the US FDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health ...

Glenmark Pharma launches triple-combination drug for Type 2 Diabetes

Medication will be sold under the brand name Zita DM, will be priced at Rs 14 per tablet

PLI scheme effect? Bulk drug imports from China slow, shows data

Experts say scheme to boost local manufacturing will take 5-7 years to show tangible results